Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation
Expert Review of Pharmacoeconomics & Outcomes Research · 03.07.2026 · 26 (6) · 783-793
DOI: 10.1080/14737167.2026.2691190 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 22.06.2026. Verfasst von Amber Tiemens und 7 weiteren Autor:innen. Beteiligte Einrichtung: Market Access and HEOR, Asc Academics B.V., Groningen, The Netherlands. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Antineoplastic Agents. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Market Access and HEOR, Asc Academics B.V., Groningen, The Netherlands.
- Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Global HEOR, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
- Market Access, Boehringer Ingelheim Portugal, Lda, Lisbon, Portugal.
- Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.
- Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Tiemens, A., Sauboin, C., Wolters, S., Bond, S. J., Bentvelzen, J. O. M., Monteiro, S., Walsh, S., & Postma, M. J. (2026). Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation. Expert Review of Pharmacoeconomics & Outcomes Research, 26(6), 783-793. https://doi.org/10.1080/14737167.2026.2691190
Vancouver
Tiemens A, Sauboin C, Wolters S, Bond SJ, Bentvelzen JOM, Monteiro S, et al. Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(6):783-793. doi:10.1080/14737167.2026.2691190
BibTeX
@article{Tiemens2026,
author = {Tiemens, Amber and Sauboin, Christophe and Wolters, Sharon and Bond, Simon James and Bentvelzen, Judith Olga Maria and Monteiro, Susana and Walsh, Seán and Postma, Maarten Jacobus},
title = {Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {6},
pages = {783--793},
doi = {10.1080/14737167.2026.2691190}
}
EUVIMED